Cargando…

Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency

OBJECTIVE: The objective of this study is to evaluate the economic benefits of immunoglobulin replacement therapy achieved subcutaneously (subcutaneous immunoglobulin, SCIG) by the rapid push method compared to intravenous infusion therapy (intravenous immunoglobulin, IVIG) in primary immune deficie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, A, Lavoie, L, Goetghebeur, M, Schellenberg, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580879/ https://www.ncbi.nlm.nih.gov/pubmed/23167310 http://dx.doi.org/10.1111/j.1365-3148.2012.01201.x

Ejemplares similares

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
por: Martin, Adriana, et al.
Publicado: (2012)

Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
por: Walter, Graham, et al.
Publicado: (2020)

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
por: Bienvenu, Boris, et al.
Publicado: (2018)

In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
por: Cozon, Grégoire Jacques Noël, et al.
Publicado: (2018)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding
por: Morgan, Clare, et al.
Publicado: (2022)

Outcomes of Intravenous Push versus Intermittent Infusion Administration of Cefepime in Critically Ill Patients
por: Smith, Susan E., et al.
Publicado: (2023)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

2562. Retrospective Analysis of Cefepime Intravenous Push versus Extended Infusion for the Treatment of Neutropenic Fever
por: Rust, Thomas J, et al.
Publicado: (2023)

Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin
por: Abghari, Pamella F., et al.
Publicado: (2017)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
por: Martin, Adriana, et al.
Publicado: (2012)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

In-line warming reduces in-line pressure of subcutaneous infusion of concentrated immunoglobulins
por: Leidenmühler, Peter, et al.
Publicado: (2023)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
por: Dolenc-Voljč, M., et al.
Publicado: (2013)

Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study
por: Cowan, Juthaporn, et al.
Publicado: (2020)

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study
por: Ritchie, Bruce, et al.
Publicado: (2022)

Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations
por: Wasserman, Richard L.
Publicado: (2008)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives
por: Papadmitriou, K., et al.
Publicado: (2015)

541 Intravenous Immunoglobulin in Leukocyte Adhesion Deficiency
por: Oropeza, Said Arablin, et al.
Publicado: (2012)

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases
por: Matza, Louis S, et al.
Publicado: (2013)

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016)

Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies
por: Cinetto, Francesco, et al.
Publicado: (2021)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
por: De Cock, Erwin, et al.
Publicado: (2016)

Pushing the agenda for intravenous push administration in outpatient parenteral antimicrobial therapy
por: Johnson, Tanner M., et al.
Publicado: (2023)

Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study
por: Palabrica, Frances Rose R., et al.
Publicado: (2013)

Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions
por: Georgiadou, Sarah, et al.
Publicado: (2019)

A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
por: Kato, Hidefumi, et al.
Publicado: (2021)

Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles
por: Abbott, Jordan K., et al.
Publicado: (2022)

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
por: Visentin, Andrea, et al.
Publicado: (2022)

602. Intravenous Push Versus Intravenous Piggyback Administration of Cephalosporin Antibiotics: Impact on Safety, Workflow, and Cost
por: Lee, Ryan, et al.
Publicado: (2021)

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
por: Gupta, Sudhir, et al.
Publicado: (2023)

Preference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLE
por: Falanga, Marina, et al.
Publicado: (2018)

Safety of rapid intravenous paracetamol infusion in paediatric patients
por: Eliasen, Astrid, et al.
Publicado: (2021)

Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion
por: Mizrahi, Meir, et al.
Publicado: (2009)

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
por: Ducruet, Thierry, et al.
Publicado: (2011)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_asb8drah7mlj3bfbhot9acih0j